UNSPSC 51393001: Quazinone

This classification denotes a phosphodiesterase inhibitor with the molecular formula C11H10ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D1Q7F6C2FP, chemically known as (r)-6-chloro-1,5-dihydro-3-methylimidazo(2,1-b)quinazolin-2(3h)-one but generally known as quazinone, which bears US NIH Compound Identifier 5000. European Medicines Agency schedules Quazinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10189MIG.

UNSPSC 51393001 Quazinone is a Commodity code that in recent state and local procurement activity maps to the purchase of naloxone and drug deactivation systems rather than to the abstract chemical name. State and local health and human services agencies are buying naloxone kits and associated drug deactivation equipment to support community health and opioid-response initiatives. The issuing bodies soliciting under this code include county health departments and state health and human services commissions. Vendors must comply with standard state and local procurement requirements including drug-free workplace certification, E-Verify eligibility confirmation, appropriate insurance coverage, and often FEMA compliance when federal funding is involved.

Recent activity appears concentrated in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in late June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, framing a broader exploratory procurement around direct-to-manufacturer prescription fulfillment and pharmacy benefit management rather than the commodity itself, suggesting the code may capture broader pharmaceutical sourcing activity beyond naloxone specifically. The Seminole County opportunity carries a two-year initial term with optional one-year renewal and does not specify explicit small-business or disadvantaged-enterprise set-asides. No other recent opportunities in the block directly parallel the naloxone procurement scope.